Broad and ERS Genomics both claim victory in latest CRISPR ruling
The Broad Institute and ERS Genomics, a company that provides access to CRISPR/Cas9 IP owned by researcher Emmanuelle Charpentier, have both claimed victory in the latest round of the CRISPR inventorship battle.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
23 September 2020 ERS Genomics, the company that provides access to CRISPR/Cas9 IP owned by researcher Emmanuelle Charpentier, has appointed Michael Arciero as vice-president of IP and commercial development.
23 January 2020 A competitor of the Broad Institute has said that a European Patent Office ruling last week has weakened the CRISPR/Cas9 patent owner’s negotiating hand in any future settlement between the parties.
2 August 2019 Tensions appear to be running high in the dispute between the Broad Institute of MIT and Harvard and the University of California, Berkeley (UC Berkeley) over which first invented the CRISPR gene-editing technology.